1st Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Third Party Drug Quality Studies. H.R.3561: PATIENT Act of 2023. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act. DEA Quotas.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); SENATE; Natl Economic Council (NEC)

Bills named: H.R. 5429 (118th), S. 2916 (118th), S. 2305 (118th), H.R. 3561 (118th), H.R. 3839 (118th), S. 775 (118th), H.R. 2880 (118th), H.R. 1503 (118th), S. 2129 (118th), H.R. 5461 (118th), S. 2780 (118th), S. 1114 (118th)

Medicare/Medicaid MMM

Medicare Part D Reform. Medicare Part D Program and Generic Drugs. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. Medicare Reimbursement for Biosimilars. H.R.1352: Increasing Access to Biosimilars Act of 2023. Medicaid Rebate Penalty.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: Natl Economic Council (NEC); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5461 (118th), S. 2129 (118th), H.R. 1352 (118th)

Copyright/Patent/Trademark CPT

Skinny Labeling. REMEDY Act. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140: Patent Eligibility Restoration Act of 2023. H.R.6986/S.3583: To address patent thickets. NIST framework of march-in rights pursuant to the Bayh-Dole Act. Restoring Americas Leadership in Innovation Act.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Institute of Standards & Technology (NIST)

Bills named: S. 3583 (118th), H.R. 4370 (118th), H.R. 6986 (118th), S. 2140 (118th), S. 2220 (118th)

Budget/Appropriations BUD

FDA Funding. Appropriations. Continuing Resolution.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.